Navigation Links
FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
Date:12/20/2011

atients with renal disease, chlorthalidone may precipitate azotemia. Consider withholding or discontinuing EDARBI or EDARBYCLOR if progressive renal impairment becomes evident.

EDARBYCLOR attenuates chlorthalidone-associated hypokalemia. Hypokalemia is a dose-dependent adverse reaction that may develop with chlorthalidone. Coadministration of digitalis may exacerbate the adverse effects of hypokalemia.

Hyperuricemia (chlorthalidone) may occur or frank gout may be precipitated in certain patients receiving chlorthalidone or other thiazide diuretics.

The most common adverse reaction that occurred more frequently with EDARBI than placebo in adults was diarrhea (2 percent versus 0.5 percent). The adverse reactions that occurred at an incidence of greater than or equal to 2 percent of EDARBYCLOR-treated patients, and greater than azilsartan medoxomil or chlorthalidone, were dizziness and fatigue. Elevations of creatinine (2 percent) were typically transient, or nonprogressive and reversible, and associated with large blood pressure reductions.

Patients receiving EDARBI or EDARBYCLOR and nonsteroidal anti-inflammatory drugs (NSAIDs) who are also elderly, volume-depleted (including those on diuretics), or who have compromised renal function due to potential reversible deterioration of renal function should have their renal function monitored periodically. NSAIDs increase risk of renal dysfunction and interfere with antihypertensive effect. Renal clearance of lithium is reduced by diuretics, such as chlorthalidone, increasing the risk of lithium toxicity.

For further information:

Please click here for complete EDARBI Prescribing Information or here'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
2. FDA Approves Hologics Cervista High Throughput Automation System for Cervical Cancer Screening
3. FDA Approves First Generic Version of Cholesterol-Lowering Drug Lipitor
4. FDA Approves First Insomnia Drug for Middle-of-the-Night Waking Followed By Difficulty Returning to Sleep
5. FDA Approves Eylea for Eye Disorder in Older People
6. FDA Approves First Supplemental Test for Chagas Disease
7. FDA Approves Erwinaze to Treat a Form of Leukemia
8. FDA Approves New York Blood Centers HEMACORD™ for Stem Cell Transplantation
9. FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer
10. FDA Approves Xarelto to Prevent Stroke in People With Common Type of Abnormal Heart Rhythm
11. FDA Approves U.S. Market Return for octagam® Following Octapharmas Implementation of Enhanced Safety Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
(Date:8/29/2014)... --  Vittamed Corporation , a neurodiagnostics medical device company based ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, ... " Teo Forcht Dagi is an experienced ... venture capital," said Remis Bistras , President and CEO ... strategic, and entrepreneurial expertise to our Board." Dr. ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... July 13 New England Biolabs (NEB) has expanded ... of NEBNext™ Quick DNA Sample Prep Reagent Set 2 and ... Roche,s 454 GS FLX Titanium™ and GS Junior™ instruments. These ... fast fragment library preparation. The Master Mix Set further streamlines ...
... July 13 Galen Advisors, a leading provider of ... for the first half of 2010.  Assaulted by rising costs, reduced ... expertise and automation of their revenue cycle. , ... Galen,s new clients include a ...
Cached Medicine Technology:New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms 2Galen Advisors Grows Client Base More Than 50% 2Galen Advisors Grows Client Base More Than 50% 3
(Date:8/31/2014)... August 31, 2014 Future Health, ... (EHR) software firm that focuses on helping doctors ... found a congruent commitment with the creators of ... , “We create an environment that assists doctors ... more time with patients,” says Steven Kraus, founder ...
(Date:8/31/2014)... Brook Forest Voices , audiobook ... & Sophistication: Short Stories of Wisdom and Kindness from ... James W. Jackson author, speaker, humanitarian and cultural economist. ... compresses his vast volume of meticulously handwritten notes taken ... countries on behalf of Project C.U.R.E . Founded ...
(Date:8/31/2014)... 2014 The severity of menopausal symptoms ... in menopause is expert in helping patients find ... from uncomfortable symptoms with the latest treatment options, including ... a variety of alternative treatments and products that can ... options may fall outside of what can be called ...
(Date:8/31/2014)... Barcelona, Spain Sunday 31 August 2014: Mortality ... at one year despite good use of oral anticoagulants, ... Atrial Fibrillation General Pilot Registry. The findings were presented ... by registry chairperson Professor Gregory Lip (Birmingham, UK). , ... sponsored registry focused on management practices of European cardiologists ...
(Date:8/30/2014)... August 2014: A new batteryless cardiac pacemaker based ... motion was presented at ESC Congress 2014 today ... does not require battery replacement. , Mr Zurbuchen, ... at ARTORG, University of Bern, Switzerland, said: "Batteries ... Once they reach a critically low energy level, ...
Breaking Medicine News(10 mins):Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 2Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 4Health News:Brook Forest Voices Announces End of Summer Release! Dr. James Jackson’s, “Simplicity & Sophistication” Audiobook 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 4Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 5Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2
... government and Delhi Public School (DPS) Society on a petition// ... 1.5 million for treatment of breast cancer. ,While ... Kapur's plea, Justice Hima Kohli asked Delhi's director of education ... 3. ,Kapoor pleaded to the court that she ...
... Center together with engineers from the university's Applied Physics ... checks a patient's finger for symptoms of Raynaud's disease. ... to be promising: ,The Ambulatory Raynaud's Monitor ... a bandage or medical tape. It contains two sensors ...
... The U.S. Food and Drug Administration (FDA) today ... Complex (Human), Alphanate. //The product is approved for ... Willebrand disease (vWD) in whom the hormone desmopressin ... approved for patients with severe vWD (Type 3) ...
... Delhi: All India Institute of Medical Sciences (AIIMS) director ... chief public relation officer filed a police complaint against ... public relation officer of AIIMS, has filed a police ... here accusing Venugopal of harassment, wrongful restraint from entering ...
... British scientists have developed a house to help people with ... a warning when it thinks there may be a problem. ... Institute of Medical Engineering could mean elderly people with fading ... rather than being forced to go into care homes, reported ...
... New Delhi: The Supreme Court Tuesday admitted a petition ... and use of non-iodised salt for human consumption. ... P.P. Naolekar and Justice R.V. Raveendran admitted the petition ... government to file its response in four weeks. ...
Cached Medicine News:Health News:Ex-teacher Sues Delhi Public School 2Health News:Space-Age Bandage Monitors Patients With Raynaud's Disease 2Health News:FDA Approves New Product to Treat Von Willebrand Disease 2Health News:AIIMS Official Files Complaint Against Venugopal 2Health News:‘Smart House’ Developed to Monitor People With Dement 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... Hoffmann® II Hybrid External Fixation System ... generation in hybrid fixation. It incorporates ... and is designed to offer speed ... patented Hoffmann® snap-fit technology. , ,Using ...
Medicine Products: